11:45 a.m. ET: Bone Biologics
12:30 p.m. ET: Advanced Bifurcation Systems
"A new wave of innovation is sweeping the life sciences sector, creating the opportunity for new therapies that save lives or improve patient care, while offering exceptional returns for investors, who employ thoughtful stock selection," said Crocker Coulson, President of CCG.
"This virtual conference will focus on companies with scientific breakthroughs to develop whole new classes of drugs, devices, therapies and diagnostic procedures. Investors, who are new to life sciences or experts in the field, will obtain a wealth of new investment ideas from the presenting companies. We are very pleased with the line-up of presenting companies and I look forward to a very stimulating conversation with Andrew Fein, a Senior Biotech Analyst and Managing Director at H.C. Wainwright," Coulson said.
These are the descriptions of the presenting companies:
BioLight (TASE: BOLT) directly invests in, manages and commercializes biomedical innovations by focusing on groups, or 'clusters,' of technologies that explore different aspects of the same medical condition. BioLight's two current clusters include ophthalmology, through its 100% owned subsidiary XL Vision; and cancer diagnostics via its 29% ownership of Micromedic (TASE: MCTC).
DelMar Pharmaceuticals (OTC: DMPI) was founded in 2010 to develop and commercialize proven cancer therapies in new orphan drug indications where patients are failing modern targeted or biologic treatments. The Company's lead asset, VAL-083, is currently undergoing clinical trials in the U.S. as a potential treatment for refractory glioblastoma multiforme, the most common and aggressive form of brain cancer. VAL-083 benefits from extensive clinical research sponsored by the U.S. National Cancer Institute, and
|SOURCE CCG Investor Relations|
Copyright©2012 PR Newswire.
All rights reserved